Gilead Sciences Climbs On Positive Earnings
Gilead Sciences, Inc. (NASDAQ: GILD)
Gilead Sciences seems to be today’s biggest story in the healthcare space. While several investors were concerned about the company’s ability to continue to produce earnings growth, those concerns were put to rest last night when the company’s earnings report for the quarter was released. As I’ve predicted for the past several weeks, GILD earnings absolutely blew analyst expectations out of the water. For the full details on earnings, click here. Nonetheless, as a result of the overwhelmingly positive earnings, Gilead Sciences shares are climbing. Currently (12:09), GILD is trading at $116.64 per share after a gain of 3.16%; which is still one heck of a discount. So, you may want to consider looking for dips as entrance opportunities.
MannKind Declines After Discounting Stock And Gaining Debt To Pay Off Debt
MannKind Corporation (NASDAQ: MNKD)
MannKind Corporation shares are down in a big way today after the company announced that it is using a mix of discounted stock and more debt in order to pay off the $100 million in convertible debt that matures in about two weeks. In the announcement, MannKind stated that they will be doing a stock for debt exchange to cover over half of their obligation. The price of these shares will be determined by the average price of MNKD over the next 10 trading days. Another $28 million of the debt will be paid via new convertible debt that will mature in 2018. As a result of the news, MNKD is currently (12:18) trading at $4.45 per share after a loss of 7.68% so far today. However, long term bulls aren’t concerned about how the debt is paid. They have faith in the fact that Afrezza is likely to be incredibly profitable in the long run. They also point to the fact that technosphere is likely to lead to new advancements in medicine in the future; which is also likely to be profitable. Nonetheless, MNKD is likely to take even more of a short-term beating as a result of their plan to settle their debt.
Ariad Pharmaceuticals Gives Up Gains
Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA)
Ariad Pharmaceuticals had an incredible day in the market yesterday. Trading on relatively high volume, we saw massive gains. However, the company is giving up much of those gains today after announcing a new finance deal in which the company will receive $100 million cash through a synthetic-royalty financing deal with PDL BioPharma, Inc. (NASDAQ: PDLI) In exchange for the financing, PDL will receive a small royalty on all future sales of Iclusig until a fixed rate of return is realized. Investors don’t seem to like the deal as we are seeing massive declines today. Currently (12:27), ARIA is trading at $7.70 per share after a loss of 6.39%. While some investors may be on edge about the deal, I’m really not concerned. It’s common to see big financing deals like this in the biotech space; and ARIA is a strong company that’s likely to grow regardless. No wonder the bulls are picking up the discounted shares today!
Nymox Pharmaceutical Corporation Getting Ready For More Movement
Nymox Pharmaceutical Corporation (NASDAQ: NYMX)
Nymox Pharmaceutical Corporation saw massive gains Monday after announcing that they had reached their primary endpoint in Phase 3 BPH studies of NX-1207. However, since Monday, we’ve seen relatively flat movement. As a result, we’re starting to see the familiar shape of a flag in the company’s stock chart. This generally insinuates that the stock is resting before the next breakout. So, this is definitely going to be one to watch!